Wearable glucose sensor use after pregnancy with gestational diabetes
Looks at how women use a glucose sensor after gestational diabetes pregnancies.
Key facts
- Who runs it
- Oregon Health and Science University
- Where
- Philadelphia, Portland, and Santa Barbara, United StatesSee the 3 sites
- Trial code
- Registry title
- Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness
- Status
- Not yet recruiting
- People taking part
- 50 people, planned
- Started
- Jan 2026
- Expected to end
- Dec 2027
- Type of study
- Observational
- Treatments tested
- Dexcom Stelo real-time Continuous Glucose Monitor
- Record updated
- 21 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who recently gave birth and had gestational diabetes (diabetes during pregnancy) in their most recent pregnancy. They will use the Dexcom Stelo glucose sensor.
- Age
- 18 Years and older
- Sex
- Female only
- Disease stage
- Gestational diabetes diagnosed during pregnancy by a 1- or 2-step Oral Glucose Tolerance Test, or a result of >= 200 mg after any glucose challenge (50g, 75g, 100g). Must be no more than 6 weeks and 6 days after giving birth. Must have a smartphone that works with the Dexcom Stelo app and read, write and understand English.
- Earlier treatment
- Cannot join if insulin was used before going home from the hospital stay for the birth. Cannot join after obesity surgery.
Main reasons for not taking part
- Type 1 or type 2 diabetes before the pregnancy
- Kidney failure needing dialysis, or heart failure
- Large skin problems at the sensor sites, or severe allergy to medical adhesives
- Insulin use before leaving the hospital after birth, or past obesity surgery
- Taking part in another postpartum glucose monitoring or lifestyle trial
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Gestational Diabetes Mellitus (GDM) diagnosis by 1- or 2-step Oral Glucose Tolerance Test (OGTT) during pregnancy or >= 200 mg following any glucose challenge (50g, 75g, 100g)
- Has a smart phone compatible to support Dexcom Stelo app
- Able to read, write, and understand English
- Meet Stelo Glucose Biosensor Indications for Use (IFU) per approved commercial labeling
- Willing to follow all study procedures
Who cannot take part
- Obesity surgery
- Insulin use prior to discharge home from the delivery admission
- Preexisting Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D)
- End-stage renal failure (on dialysis)
- Heart failure
- Other uncontrolled high-risk condition as determined exclusionary by site investigators
- Extensive skin changes/diseases that preclude wearing the required system on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites
- Known severe allergy to medical-grade adhesives
- Any condition that, in the opinion of the investigator, would interfere with their participation in the trial
- Current participation in another postpartum Continuous Glucose Monitoring (CGM) or lifestyle intervention trial
- Greater than 6 weeks and 6 days postpartum at enrollment
Where in United States
- University of PennsylvaniaPhiladelphia, United StatesContact: Elizabeth NortonNot yet recruiting
- Oregon Health Science UniversityPortland, United StatesContact: Christian Huertas PaganNot yet recruiting
- Sansum Diabetes Research InstituteSanta Barbara, United StatesContact: Alex AlChwikani, Recruitment SpecialistNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this prospective observational study is to gather exploratory and practical use data of the Dexcom Stelo Glucose Biosensing System (Stelo), an over-the-counter (OTC) real-time Continuous Glucose Monitoring (CGM) system among patients with Gestational Diabetes Mellitus (GDM) in their most recent pregnancy.
The group in the trial
- Postpartum Stelo Users
Postpartum individuals with their most recent pregnancy complicated by Gestational Diabetes Mellitus (GDM)
Treatment: Dexcom Stelo real-time Continuous Glucose Monitor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness
- Plain-language title
- Wearable glucose sensor use after pregnancy with gestational diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 21 January 2026